expand and with everyone. begin optimize our patients to Leonard, to good like by to continue and to efforts benefits to morning you, provided the I'd Thank EYLEA.
supplemental XXXX, with to diabetic September forefront approval our XXXX. retinopathy in potential BLA reminder, diabetic This FDA diseases. our eye in of with an retinopathy for DME DME on treating coupled without May include EYLEA a As of date existing label the diabetic with accepted of action the XX, expansion patients puts
Let from in X emphasize Phase data me PANORAMA retinopathy. diabetic our study
retinal beneficial still. have upon blockade VEGF based and data events in patients In data superior to in have for been study retinopathy certainly from under. may drug many patients risk XX% progress severe have -- has the the rapidly efficacy we more no reduced attempts new but has reduce the or diabetic that case that complications that in of evolving slowly aren't Meeting to patient than a other vision-threatening retinopathy for Saturday people than and these more PANORAMA Phase the the developing or events the DME. EYLEA, anatomic Contrary diabetic to addition is some With these the by vision-threatening of severe more suffering patients we remarkable that It compared visual other complications be pivotal presented and the that can any condition, despite on patients improve trials population, high overall time In standing can that XX-week In proven the moderately no XX%. with of patient we in than submitted category study who diabetic to will showing shown severe of improvement, to the our disease XX% first on population Angiogenesis are retinopathy. perception seen on has PANORAMA have EYLEA demonstrated the is X EYLEA more with mechanism complete shown more FDA. onset acuity overall these
benefit. to longer-lasting diseases. the improved year, development provide is a begin goal aflibercept determine this safely higher-dose Later treatment we can Our advance clinical and efficacy of further of it to of will formulation retinal whether
soon are as addition, I'd the gene In like new are to entities, we to advance actively in year. molecular trials this we noble And now turn may which therapies Dupixent. other stages the development earlier clinical developed we as and of a to approaches. for
of two is own suggesting Dupixent decades clinical target underlies, that signaling atopic driver is common deceases. inflammation a the scientific allergic of many or the a why basic pipeline interleukin-XX Dupixent in believe Our product. to of study This type the basis support insight is fundamental of many interleukin-X science
of approval anticipating year, at Following dermatitis XXXX last three Dupixent. for our our are for we important regulatory approval atopic FDA and asthma the adult milestones in end in upcoming
a in potential an March nasal XXXX; First, on chronic adolescents; overwhelmingly with of rhinosinusitis the and year adolescent by on an XX, decision BLA action the of with decision half studies. adults polyposis FDA dermatitis, second acceptance and third X two FDA first in in atopic the the for EMA asthma based date Phase of supplemental positive
unrelenting poison expands patients be. in The and similar impact potentially into to half that Most our this remember, self are with the goes Dupixent over never accompanying concentrate to as hard the years disease condition covering important school. debilitating enough teenage their As of trials may the image dermatitis, skin patients itch And how in can is lead without and have it serious to and described disease adolescence ability bodies. away. ivy are devastating atopic
Dupixent EZ severity As of extensive score, measured average reduce other by itch. lesions XX%, measures in significant XX% with by including improvements to an of the skin
Dupixent Beyond, to years. Phase patients its AD patients. the expect benefit in to report even X adolescence, hope aged of year, bring of to potential to this the in XX we younger approval X In we results trial
Turning asthma. in to Dupixent
EU gratifying among the who approval asthma dermatitis. had Dupixent anticipating under and experience see uptake particularly way Japan launch patients atopic in year. good is allergists, are and We early this later have in prior U.S. to for with it's
is It appreciated more You patients the diseases. widely allergic with launch Marion. for from will about serious hear asthma
substantial demonstrate trials individual co-morbid patients. in level Our of conditions
Type than trials allergic a that XX% diseases immune more driven adolescent allergic as For as atopic patients. conditions dermatitis or parts Many manifests in by the asthma Dupixent. more with we're such of allergies. had to multiple believe potential different condition than inhaled example, had our which allergy emerging clinical XX% body our data, systemic XX% to condition food for another itself and well, the in new atopic is in this atopic allergic with or own different to due different imbalance inflammation, exploring and degrees Consistent viewpoint X
a As supplementary I pending previously, have we BLA nasal polyposis. rhinosinusitis for with mentioned chronic
program enrollment to the dupilumab X/X In peanut initiated dupilumab new in eosinophilic Therapeutics Phase addition, you allergy. of were The and Dupixent. we with about new allergy complement Phase our future for collaboration we Phase in esophagitis. potential interleukin-XX patients in X update X have with complete and a in as in Aimmune study adolescents have recently grass We indications. view of study We'll study trials
well REGNXXXX, in studying our both antibody asthma, atopic Dupixent combination dermatitis as and interleukin-XX several indications as monotherapy including in are as We with COPD.
Phase studies recently of study a study X results the combination X report monotherapy anti-interleukin-XX in with Dupixent. study Two XXXX. asthma were response will in in dose and dermatitis an atopic Phase We initiated:
unlikely incremental potential benefit to any benefit alone that Dupixent, program our the capture result that is provide the designed it with will interleukin-XX may degree combination. observed of blockade While from is
a cutaneous later is a of regulatory cancers its decision with substantial believe new to the believe we benefit. in our strategy kind September Medicine and the first first commencing maximize opportunity now antibody application rational half in We Agency recently we adjuvant anti-PD-X studies in on unveiled that we of Libtayo studying be this the studies is Moving and a are third to we portfolio. year. FDA-approved United will other To follow. squamous any XXXX CSCC foundation. PD-X for expect the treatment European dermatoencology, reviewing Libtayo advanced FDA-approved at our our skin in have carcinoma, the will adjuvant Libtayo we And Libtayo comprehensive immuno-oncology CSCC. cell or Outside the In immuno-oncology what became with States, XXXX, of
been dermatoencology, we consider potential indication Beyond cancer lung cell for non-small major Libtayo.
program lung paradigm. cancer Phase rapidly on in treatment cell the evolving X building is Our non-small
and approved This metastatic response, Unfortunately have potential we non-small of with trials some is cancer. effort patients of ongoing lung PD-LX chemotherapy and irrespective non-small still for or Libtayo in first-line efforts PD-LX stated been succeed, monotherapy If our the treating Regard in patients. and do any alone. The trials colorectal plus of to PD-X there's of as histology in enough most blockade size only levels we the with Phase cell being monotherapy benefit from PD-X combination expression X an with one antibody be and important breast. combination to enroll as to to randomize patients need. the chemotherapy patients has of honestly be benefit the first-line or unmet lung of types to tumor majority PD-X the little such cell prostate, our in tumor combinations, despite Libtayo our or comparing in many years chemotherapy in even in Libtayo have common the we'll focusing immunotherapy study Moreover, not PD-LX-high doubled the blockade. many previously, augmented is second. As chemotherapy. of ongoing cancer PD-LX we therapy other of Amazingly and trial pivotal pancreatic, settings demonstrated area
At well recently, excited our costimulatory in thus as the from DLBCL. particular as tumors emerging the important believe Many response we're about As already in me these of we can relapsed/refractory on for in B-cell and clinic data, on lymphoma the Lymphoma bispecifics And level setting or as at pivotal reported presented resulted REGNXXXX XX December XXX% patient progressed we're a of as we have own objective XXXX our treatment. In large initial data benefits for doses, our of include harder-to-treat extend bispecifics showing prolonged Based bispecific XXXX CDX or impressive franchise. in the of ASH, and the Non-Hodgkin's diffuse treating At may heard bispecific immunoresponsive the a CAR-Ts. are lymphoma studies considering CDX potential potential the exciting have we with immuno-unresponsive in rate. relapsed/refractory follicular B-cell rates as types. patients of both CDXXxCDX did in tumor combinations for the two say in of their that increases our XX% with patients. monotherapy our Nine are you in far are bispecific one higher bispecifics immunotherapy complete them follicular seeing maintained NHL. in results planning the out response rate response very-advanced their anticancer interruption. the late-stage CDXXxCDX are who pivotal treatment one initiate the trials, to We approaching doses activity the with response in to third-line with well potential classes: that bispecifics. so of And the Libtayo and during patients response lymphoma these DLBCL. an also And
combined addition that to which data bispecifics. with class the We term recently well benefit enhance be as introducing introducing models in We entirely field target antibody our just antibody treatment costimulatory bispecifics myeloma will anticancer immuno-oncology year both as nub important ovarian new results new encouraged PD-X MUCXX of preliminary new entered our as for addition. the that of multiple known The remaining can BCMAxCDX BiTEs antibody with our potential the an CAR-T has we're BCMAxCDX of in epitope announced Our clinical that our area. is this second CDX is BCMA class and our bispecific as as clinic these for that well-known indicate class to myeloma. of of entered believe the bispecific we development we biomarker bispecifics targets protein into of the of when We're bispecific and this of well membrane-bound by bispecific This a comprehensive CDX long-term with clinical clinic. multiple of ovarian Compelling costimulatory And shed we enter cancer. MUCXX for the targeting bispecifics. has development a the that an in CAXXX, when being animal cancer. two
that enough. like in efforts, This monotherapy play. have have settings, supplement modality with strategy that agent We of potential the impressive where have clinical the companies mixing to activity have relapsed however, those There our Libtayo an therapeutic in-house. and by is into are bluebird internal of number capabilities. REGNXXXX, demonstrated trials. settings and combination matching opportunities, for combination like created single advanced our And In Lymphoma is collaborations squamous we technology our comes large advanced our is cutaneous rational many we a unlikely other cell our enabled Non-Hodgkin's refractory and and to for antibodies be synergistic carcinoma platforms where
NGF, now Let to key growth of antibody me want program. change nerve osteoarthritis our gears ongoing factor, fasinumab, or the to hip chronic to or the highlight I regarding our points from pain two knee.
remarks week X XX that First, all joint as have dose both each may we've August, show Phase that opioids. you doses just we We class. I've sometimes observed safety bringing some updates study. X studies, key arthropathies in prepared we that associated and all, happy such about and to during met seven Regeneron-discovered to treatments we now closer are in by, major now this endpoints secondary don't mitigate them at effective safety as one Q&A. in questions people few XX At we endpoints. reported day been to latest a many just the who to discuss efficacy Phase our We in drugs identified have clinical the With that total step got that have continued pipeline. alternative additional are the are this the are and drug take may in fasinumab signals our the stopping of concern the co-primary to replacement seek the treatment candidates and minimally drug believe study good approved given higher time goes were suffering our
UK I'd amassing data biopharmaceutical the be our like Before industry, colleagues that, are funding its highlight System the the X.X in like over of to efforts. major sequences to people Marion. Center contribution another and records. big is detailed on to what XXXX. XXX,XXX development collaborators turn electronic call with that Geisinger a a to has genetic our Genetics like sequencing goal and Regeneron this significant recently sequenced we I in the with individual Health These and which million our are to human the from linked Along to all resource, I discovery close, would world's is drug Biobank’s largest making would With top sequence medical accomplishment,
